晚期肺腺癌M2-TAMs浸润与EGFR-TKIs治疗疗效的关系

Correlation of M2-polarized Tumor-associated Macrophages and the Treatment Response of EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma

目的探讨人晚期肺腺癌M2活化的肿瘤相关巨噬细胞(M2 tumor-associated macrophages,M2-TAMs)浸润与表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)治疗疗效之间的关系。方法收集88例二线使用EGFR-TKIs治疗的晚期肺腺癌病例,采用双标免疫荧光染色法检测全部患者的M2-TAMs浸润情况,采用扩增突变阻滞系统(aplification refhctory mutation system,ARMS)法检测其中61例患者的EGFR基因突变,分析M2-TAMs计数与患者EGFR-TKIs治疗疗效之间的关系。结果无论在全部肺腺癌患者、61例已知EGFR基因状态患者,还是在49例EGFR基因突变的患者中,疗效为进展(progressive disease,PD)的患者M2-TAMs计数均明显高于疗效为非PD的患者(P<0.01)。结论无论EGFR基因突变状况如何,M2-TAMs浸润均与晚期肺腺癌EGFR-TKIs治疗疗效呈负相关。

Objective To determine the correlation of M2-polarized tumor-associated macrophages（M2-TAMs）and the treatment response of epidermal growth factor receptor-tyrosine kinase inhibitors（EGFR-TKIs）in patients with advanced lung adenocarcinoma.Methods A total of 88 advanced lung adenocarcinoma patients treated with second-line EGFR-TKIs was involved in this study.M2-TAMs infiltration was detected by double-labelled immunofluorescence staining in all the patients.EGFR mutation status was detected by aplification refhctory mutation system（ARMS）method in61 cases.The relationship between M2-TAMs counts and EGFR-TKIs treatment response was analyzed.Results M2-TAMs counts were significantly higher in patients with progressive disease（PD）than those without it（P〈0.01）.A trend also remained in patients with known EGFR status（n=61）and those with mutant EGFR（n=49）.Conclusion Irrespective of EGFR mutation,M2-TAMs are related to the decreased response of EGFR-TKIs in advanced lung adenocarcinoma.